
New data for management of hepatocellular carcinoma
The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration
The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials
Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.